Johannes D Veldhuis1, Catalina Norman, John M Miles, Cyril Y Bowers. 1. Endocrine Research Unit, Mayo School of Graduate Medical Education, National Institutes of Health Center for Translational Science Activities, Mayo Clinic, Rochester, Minnesota 55905, USA. veldhuis.johannes@mayo.edu
Abstract
CONTEXT: Ghrelin is a potent endogenous stimulator of GH secretion. However, clinical factors that regulate ghrelin dose-responsiveness are incompletely defined. OBJECTIVE: The aim of the study was to test the multipathway hypothesis that testosterone (T) and estradiol, GHRH, and somatostatin (SS) jointly modulate ghrelin's action. DESIGN/PARTICIPANTS/ SETTING: Healthy older men (n = 21) participated in a double-blind, prospectively randomized, placebo (Pl)-controlled study in a Clinical Translational Research Center. INTERVENTIONS: To create a range of sex-steroid milieus, men received leuprolide + Pl (n = 10) or leuprolide + T addback (n = 11). Sixteen to 21 d later, subjects received three separate randomly ordered overnight constant i.v. infusions of saline, GHRH, and SS. Interactions between the peptide clamp and ghrelin were tested by superimposed injections of four randomly ordered bolus i.v. doses of ghrelin (0.03, 0.135, 0.60, and 2.7 μg/kg). GH was measured every 10 min, and GH responses were assessed by nonlinear dose-response analysis. Linear associations were assessed by stepwise regression. OUTCOME MEASURES/ RESULTS: The descending numerical order of ghrelin efficacy (maximal GH secretory-burst mass; micrograms/liter) was 107 (GHRH + Pl), 104 (GHRH + T), 73 (saline + T), 73 (SS + T), 60 (saline + Pl), and 52 (SS + Pl) [means], wherein SS + T exceeded SS + Pl. GHRH and IGF binding protein-1 augmented, whereas IGF-I attenuated ghrelin potency. Age and IGF-I decreased ghrelin/GHRH synergy. Ghrelin sensitivity was independent of interventions. CONCLUSIONS: These studies introduce composite regulatory effects of sex hormones, GHRH, SS, IGF binding protein-1, and IGF-I on ghrelin dose-responsiveness, suggesting multipathway modulation of GH-secretagogue action.
CONTEXT: Ghrelin is a potent endogenous stimulator of GH secretion. However, clinical factors that regulate ghrelin dose-responsiveness are incompletely defined. OBJECTIVE: The aim of the study was to test the multipathway hypothesis that testosterone (T) and estradiol, GHRH, and somatostatin (SS) jointly modulate ghrelin's action. DESIGN/PARTICIPANTS/ SETTING: Healthy older men (n = 21) participated in a double-blind, prospectively randomized, placebo (Pl)-controlled study in a Clinical Translational Research Center. INTERVENTIONS: To create a range of sex-steroid milieus, men received leuprolide + Pl (n = 10) or leuprolide + T addback (n = 11). Sixteen to 21 d later, subjects received three separate randomly ordered overnight constant i.v. infusions of saline, GHRH, and SS. Interactions between the peptide clamp and ghrelin were tested by superimposed injections of four randomly ordered bolus i.v. doses of ghrelin (0.03, 0.135, 0.60, and 2.7 μg/kg). GH was measured every 10 min, and GH responses were assessed by nonlinear dose-response analysis. Linear associations were assessed by stepwise regression. OUTCOME MEASURES/ RESULTS: The descending numerical order of ghrelin efficacy (maximal GH secretory-burst mass; micrograms/liter) was 107 (GHRH + Pl), 104 (GHRH + T), 73 (saline + T), 73 (SS + T), 60 (saline + Pl), and 52 (SS + Pl) [means], wherein SS + T exceeded SS + Pl. GHRH and IGF binding protein-1 augmented, whereas IGF-I attenuated ghrelin potency. Age and IGF-I decreased ghrelin/GHRH synergy. Ghrelin sensitivity was independent of interventions. CONCLUSIONS: These studies introduce composite regulatory effects of sex hormones, GHRH, SS, IGF binding protein-1, and IGF-I on ghrelin dose-responsiveness, suggesting multipathway modulation of GH-secretagogue action.
Authors: M J Bray; T M Vick; N Shah; S M Anderson; L W Rice; A Iranmanesh; W S Evans; J D Veldhuis Journal: J Clin Endocrinol Metab Date: 2001-07 Impact factor: 5.958
Authors: Petra Kok; Remberto C Paulo; Mihaela Cosma; Kristi L Mielke; John M Miles; Cyril Y Bowers; Johannes D Veldhuis Journal: J Clin Endocrinol Metab Date: 2008-07-08 Impact factor: 5.958
Authors: Catalina Norman; Nanette Rollene; Suanne M Weist; Jean R Wigham; Dana Erickson; John M Miles; Cyril Y Bowers; Johannes D Veldhuis Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Catalina Norman; John Miles; Cyril Y Bowers; Johannes D Veldhuis Journal: Am J Physiol Regul Integr Comp Physiol Date: 2013-03-13 Impact factor: 3.619
Authors: Johannes D Veldhuis; Rebecca J Yang; Jean R Wigham; Dana Erickson; John C Miles; Cyril Y Bowers Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958
Authors: Lara Pena-Bello; Sonia Pertega-Diaz; Elena Outeiriño-Blanco; Jesus Garcia-Buela; Sulay Tovar; Susana Sangiao-Alvarellos; Carlos Dieguez; Fernando Cordido Journal: PLoS One Date: 2015-03-17 Impact factor: 3.240